focus -WSS

focus

author：fashion 2025-09-06 02:15:20 - browse：75825

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： My chronic pain journey would have been easier knowing 5 things % STAT

leisure time

explore

WSS

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Thousands protest in Iraq for a second day over burning of Quran in Sweden

My chronic pain journey would have been easier knowing 5 things % STAT

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Burning questions about Delta and the next phase of the Covid pandemic

What Henrietta Lacks's story taught me about my role as a doctor

focus

focus

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FAMU bans football players from facility after release of rap video shot in team's locker room

United colonoscopy coverage change 'may cost lives,' doctors say

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

Hepatitis C has a cure — but many Americans still lack access to it

GOP inquiry over gain

Continuity nursing helped my family in our darkest PICU moments

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Drug repurposing or repositioning? The language matters

Burning questions about Delta and the next phase of the Covid pandemic

focus

Ukrainian soldiers say they owe lives to US

How a key Senate committee is planning to regulate PBMs

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

Why do we get seasonal allergies?

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Thousands protest mob assault of women who were paraded naked in remote Indian border state

hotspot

leisure time

explore

Wikipedia